Standout Papers

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 D... 2013 2026 2017 2021 742
  1. Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease (2013)
    Sunder Mudaliar, Robert R. Henry et al. Gastroenterology

Immediate Impact

20 from Science/Nature 97 standout
Sub-graph 1 of 19

Citing Papers

Antisense oligonucleotide therapeutic approach for Timothy syndrome
2024 StandoutNature
Acquisition of epithelial plasticity in human chronic liver disease
2024 StandoutNature
2 intermediate papers

Works of Linda Morrow being referenced

Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans
2020
Antisense Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
2016
and 1 more

Author Peers

Author Last Decade Papers Cites
Linda Morrow 1795 1124 1095 81 3.5k
Wei Mu 974 854 1613 77 5.9k
Mark M. Smits 2362 1321 790 69 3.6k
Carmen Roncal 1631 907 1628 87 6.0k
Giacomo Ruotolo 2002 1366 854 90 4.2k
Yoshimasa Aso 1565 787 986 155 4.2k
Xuefeng Yu 1531 566 735 130 4.2k
Franco Arturi 2736 745 1369 143 4.5k
Chang Hee Jung 1512 737 788 169 4.1k
Martin Ridderstråle 1371 608 1421 82 3.6k
Hiroshi Noto 1356 532 1041 75 2.9k

All Works

Loading papers...

Rankless by CCL
2026